NCT05450562View on ClinicalTrials.gov

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

December 25, 2025

Study Completion Date

December 25, 2025

Conditions
Neoplasm
Interventions
BIOLOGICAL

SAR444200

Sterile lyophilized powder for solution for infusion Route of administration: intravenous (IV) infusion

BIOLOGICAL

Atezolizumab

concentrate for solution for infusion Route of administration: intravenous (IV) infusion

Trial Locations (13)

10029

Icahn School of Medicine at Mount Sinai- Site Number : 8400005, New York

77030

The University of Texas MD Anderson Cancer Center- Site Number : 8400003, Houston

90033

USC Norris Comprehensive Cancer Center- Site Number : 8400004, Los Angeles

119074

Investigational Site Number : 7020002, Singapore

169610

Investigational Site Number : 7020003, Singapore

200120

Investigational Site Number : 1560001, Shanghai

308433

Investigational Site Number : 7020001, Singapore

430022

Investigational Site Number : 1560002, Wuhan

02903

Lifespan Corporation- Site Number : 8400002, Providence

M5G 2M9

Investigational Site Number : 1240002, Toronto

G1R 2J6

Investigational Site Number : 1240001, Québec

05505

Investigational Site Number : 4100002, Seoul

06351

Investigational Site Number : 4100001, Seoul

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT05450562 - Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter